Skip to main content

Table 1 Genomic Alterations Identified by Hybrid Capture

From: Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

Gene Alteration

Loss or Gain of Function

Predictor of Response to Pembrolizumab

CD274 (PD-L1) amplification

Gain

Yes

STK11 S216F and LOH

Loss

Negative predictor

MYC amplification

Gain

No

APC E2516

Loss

No

RB1

Loss

No

TP 53 R158 L

Loss

No